SCHEMBL24140751

SCHEMBL24140751

COc1cc(-c2nc3cc(N4CCN(C(C)=O)CC4)ccc3[nH]2)cc(O)c1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.52
▸ KDM4E B2RXH2 3/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ MAPT P10636 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ GAA P10253 1/20 0.52
▸ BLM P54132 1/20 0.52
▸ RXFP1 Q9HBX9 1/20 0.52
▸ BRD4 O60885 2/20 0.47
▸ TGFBR1 P36897 1/20 0.46
▸ ACVR1 Q04771 1/20 0.46
▸ AMY1A P0DUB6 4/20 0.45
▸ CHEK2 O96017 1/20 0.44
▸ ALK Q9UM73 6/20 0.44
▸ POLB P06746 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ PDE3B Q13370 1/20 0.42
▸ PDE3A Q14432 1/20 0.42
▸ NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30472177 0.88 AMY1A (0.46) ALDH1A1KDM4ESMN1; SMN2MEN1MAPT
SCHEMBL25311414 0.88 AMY1A (0.46) ALDH1A1KDM4ESMN1; SMN2MEN1MAPT
SCHEMBL24140668 0.88 ALDH1A1 (0.50) ALDH1A1KDM4ESMN1; SMN2MEN1MAPT
SCHEMBL30472123 0.88 PDE3B (0.50) ALDH1A1KDM4ESMN1; SMN2MEN1MAPT
SCHEMBL24140876 0.88 PDE3B (0.50) ALDH1A1KDM4ESMN1; SMN2MEN1MAPT
SCHEMBL24141174 0.88 ALDH1A1 (0.67) ALDH1A1KDM4ESMN1; SMN2MEN1MAPT
SCHEMBL24140757 0.87 ALDH1A1 (0.54) ALDH1A1KDM4ESMN1; SMN2MEN1MAPT
SCHEMBL24140799 0.87 ALDH1A1 (0.54) ALDH1A1KDM4ESMN1; SMN2MEN1MAPT
SCHEMBL24140737 0.87 KDM4E (0.47) ALDH1A1KDM4ESMN1; SMN2MEN1MAPT
SCHEMBL24141188 0.87 CHEK2 (0.53) ALDH1A1KDM4ESMN1; SMN2MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 — — US disclosed
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 — — US disclosed
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 — — US disclosed
WO-2021263079-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. (US) 2021-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF FEN1, ERCC4, DCLRE1B ALDH1A1 1451/4885KDM4E 2430/4885SMN1; SMN2 1598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback